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Introduction
The effectiveness of the rotavirus vaccine has been examined in 
different ecological and post-marketing studies, mainly coming 
from the US and related to the pentavalent vaccine.1-3 In Spain 
both the monovalent (RotarixTM-GlaxoSmithKline) and pentava-
lent (RotateqTM-Merck/sanofi pasteurMSD) rotavirus vaccine are 
available since 2007. The Vaccine Advisory Board of the Pediatric 
Spanish Association (AEP, www.aeped.es) recommended univer-
sal immunization against rotavirus and included this vaccine 
in the recommended child inmmunization schedule in 2008, 
although it is not reimbursed by the healthcare system.4,5 We have 
prospectively estimated the effectiveness of rotavirus vaccination 
in Spain.
Results
The study was offered to 505 children under 2 years old: 12 
rejected to participate and 26 did not complete the study and/or 
were withdrawn because of missing data in any of the study end-
points. Finally 467 patients suffering acute gastroenteritis with a 
mean age of 12.2 ± 6.3 months were included. 151 (32.3%) were 
caused by rotavirus and 163 (35.0%) had received at least one 
dose of rotavirus vaccine (56.4% received monovalent vs. 43.6% 
pentavalent vaccine) (Table 1). Mean duration of the episode was 
7.6 ± 3.6 days with a maximum number of bowel motions per 
day of 7.1 ± 3.6. Each child required a mean of 2.1±1.2 medical 
visits during the disease, and 130 patients (27.8%) required hos-
pital admission, with a mean stay of 4.6 ± 2.1 days. Patients with 
With the aim of determining rotavirus vaccine effectiveness (rVVe) in Spain, from october 2008/June 2009, 467 
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rotavirus acute gastroenteritis (RAGE) were admitted to hospital 
more frequently (50.3% vs. 17.1%, p < 0.001).
Rotavirus vaccination effectiveness (RVVE)—after receiving 
at least one dose of either vaccine—was 91.5% (95% confidence 
interval: 83.7%–95.6%) to prevent any episodes of RAGE and 
95.6% (85.6%–98.6%) to prevent hospital admission due to 
RAGE (Table 2). There were no significant differences in vac-
cine effectiveness regarding the type of vaccine used: monova-
lent and pentavalent RVVE against RAGE hospitalization were 
97.5% (81.5–99.6%) and 92.9% (70.0–98.3%), respectively. 
RVVE was higher when only children fully vaccinated were con-
sidered for the analysis: 98.3% (87.4–99.8%). No differences 
were found in RVVE in fully vaccinated children depending on 
the vaccine applied (Table 2). RVVE in children partially vac-
cinated although smaller was significant: 84.0% (45.5%–95.3%) 
to prevent any episodes of RAGE and 89.4% (53.9%–97.5%) to 
prevent hospital admission due to RAGE. The rest of effective-
ness estimations are summarized in Table 2.
Discussion
According to our results, immunization against rotavirus with 
either monovalent or pentavalent vaccine was highly effective 
in preventing any episode of acute gastroenteritis due to rota-
virus. This protection is apparent from the first dose of vac-
cine, although the effectiveness is substantially lower than that 
achieved after completing the vaccine schedule.
Our results are consistent with those reported for Europe, US 
and Latin America.1-3,6-8 The pentavalent rotavirus vaccine had 
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hospitalized gastroenteritis cases tested.8 Our estimated rotavirus 
vaccine effectiveness is much higher than that observed in low 
income countries; the reasons for such differences, although not 
fully understood, might be related with factors such as malnu-
trition, breast milk antibodies interference or the interaction of 
other enteric pathogens, among other factors.9-11
In our study, the vaccine effectiveness against any episode of 
rotavirus acute gastroenteritis regardless its severity was remark-
ably high, and not significantly different than that estimated for 
prevention of hospitalization due to rotavirus—the main outcome 
shown a high efficacy in Europe, with a reduction in the rate 
of either hospitalizations or emergency department visits due to 
acute rotavirus gastroenteritis of 94.5% for up to 2 years after 
vaccination.6 The effect of rotavirus universal mass vaccination 
in the Austrian population one season after vaccine introduction 
showed a 74% reduction in hospitalization due to RAGE with an 
average vaccine coverage of 72%.7 More recent data coming from 
Belgium—where both vaccines are available with about 80% 
government subsidization of the public price—revealed a 66% 
reduction in the percentage of rotavirus positive cases out of all 
Table 1. Summary of patient characteristics
GLOBAL (All  etiologies) 
(n = 467)
Gastroenteritis by rotavirus 
(n = 151)





0–6 months 103 (22.1%) 28 (18.5%) 75 (23.7%) 0.390
7–12 months 131 (28.1%) 42 (27.8%) 89 (28.2%)
13–24 months 233 (49.9%) 81 (53.6%) 152 (48.1%)
Sex (male %) 267 (57.2%) 91 (60.3%) 176 (55.7%) 0.351
Rotavirus vaccination <0.001
No 304 (65.1%) 140 (92.7%) 164 (51.9%)
Complete 138 (29.6%) 8 (5.3%) 130 (41.1%)
partial* 25 (5.4%) 3 (2.0%) 22 (7.0%)
Maximum number of depositions 
in 24 hours
7.1 ± 3.6 8.4 ± 4.1 6.5 ± 3.2 <0.001
Gastroenteritis episode duration 
(days)
7.6 ± 3.6 7.6 ± 3.0 7.5 ± 3.9 0.172
Hospital admission 130 (27.8%) 76 (50.3%) 54 (17.1%) <0.001
Length of hospital stay (days) 4.6 ± 2.1 4.6 ± 2.1 4.5 ± 2.2 0.519
(*) represents those children that received at least one dose of either vaccine.
Table 2. Summary of estimated rotavirus vaccine effectiveness in children below 2 years of age expressed as % (95% CI)
Effectiveness to prevent any episode of 
rotavirus gastroenteritis in:
Effectiveness to prevent hospitalization 
by rotavirus gastroenteritis in:
- Children 0–2 years old that have received at least 
one dose of either vaccine 
 
(a) only those with monovalent vaccine# 
 











- Children 0–2 years old fully vaccinated  
with either vaccine
(a) only those with monovalent vaccine#
 











- Children 0–2 years old partially vaccinated  
with either vaccine*
(a) only those with monovalent vaccine# 
 











*those children that have received only one dose of the monovalent rotavirus vaccine, or one or two doses of the pentavalent rotavirus vaccine.
# this data is only informative. the study was not designed to assess differences in effectiveness of individual vaccines and sample size is too small. 
See text for further explanations.
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region and using the same methodology during the same study 
period, and the conservative approach applied make our results 
and conclusions highly consistent and representative.
In conclusion, both rotavirus vaccines seem to have an out-
standing effectiveness in Spain. We believe that these encouraging 
results should be taken into account in rotavirus vaccine policies 
and inform practical recommendations from both the individual 
and the public health perspectives, namely, its official recommen-
dation and universal availability free of charge for all infants.
Material and Methods
A prospective, observational multicentre study was conducted 
from October 2008 through June 2009 using a pediatric research 
network (ReGALIP, www.regalip.org) that includes primary, 
emergency and hospital care settings. Any patient up to 5 years 
old seeking care because of an acute gastroenteritis (AGE) episode 
was considered eligible for the study provided that they fulfilled 
the following conditions: (a) three or more bowel motions less 
consistent than usual, whether associated to vomiting or not, in a 
24-hour period; (b) symptoms must have occurred within 7 days 
of enrollment, preceded by a 14-day symptom-free period; (c) 
an episode of acute gastroenteritis must not have occurred in the 
two weeks prior to the onset of current symptoms. Clinical and 
epidemiological data were recorded. Vaccination date and num-
ber of doses received were also registered and verified through the 
patient’s vaccination record. Also non-medical expenses incurred 
throughout the episode were collected in detail as an independent 
part of the project (see www.rotacost.org for detailed informa-
tion). At least one fecal immunoassay for rotavirus detection in 
a fecal sample was performed in all included patients (VIKIA 
Rota-Adeno®, Biomerieux). The stool specimens were obtained 
in the inclusion visit, either provided by the parent in the diaper 
or through a plastic adhesive bag or obtaining a sample with a 
rectal swab.
Only the data obtained from those patients under 2 years of 
age at inclusion and thus eligible for vaccination against rota-
virus during the study period, were analyzed in this study. A 
descriptive analysis of AGE episodes was performed. Results are 
shown as frequencies and percentages or mean ± standard devia-
tion, as needed. Differences between episodes of acute gastroen-
teritis positive and negative to rotavirus were assessed with the 
chi-squared test and the Mann-Whitney test for qualitative and 
quantitative variables, respectively. Crude odds ratios (OR) were 
calculated from the comparison of the frequency of rotavirus 
vaccination in patients with any episode of acute gastroenteritis 
positive and negative to rotavirus etiology, respectively. Rotavirus 
vaccine global effectiveness was estimated as 1-odds ratio, with 
its 95% confidence interval. Rotavirus vaccine effectiveness 
(RVVE) to prevent hospital admission due to rotavirus AGE 
(RAGE) was also calculated in the same manner. These estima-
tions were calculated for children below 2 years old, those eligible 
to have received rotavirus vaccine. Any patient receiving at least 
one dose of either vaccine was considered partially vaccinated. 
Any patient having received a full series of either vaccine (either 
2 doses of monovalent vaccine or 3 doses of pentavalente vaccine) 
considered in rotavirus clinical trials. A potential explanation for 
this might be the over-representation of severe cases, however the 
recruiting network included both primary, emergency room and 
hospital care patients. In Spain most pediatric emergency rooms 
of hospitals function as continuous care points and the popula-
tion seen there does not differ from that of primary care. Also, 
the hospitalization rate in our series matches previously reported 
rates for Spain.12,13 Only long term surveillance and population 
community-based database systematic studies might corroborate 
this finding. If this was the case, the impact of vaccine effective-
ness in vaccination efficiency would be of great importance.




 and G9 represented >99% 
of circulating rotaviruses.4,5 Universal rotavirus vaccination with 
any of the available vaccines is recommended by the Pediatric 
Spanish Association since 2008.4,5 However, none of the vaccines 
is reimbursed and parents will fully cover vaccine cost: 200.50 
euros for the 3 doses of Rotateq® or 181.20 euros for the 2 doses 
of Rotarix® (GSK). Like in our study, each vaccine available 
accounts for approximately half of the market. The effectiveness 
of both vaccines was comparable for rotavirus hospitalization 
prevention anytime the child completed the vaccination sched-
ule. The effectiveness of partial vaccination was smaller in those 
receiving 1 dose of the monovalent vaccine compared to 1 or 2 
doses of the pentavalent vaccine; however the reduced sample size 
precludes any definite conclusion on this point. Our study was 
not designed and/or powered to assess differences in effectiveness 
between vaccines.
The mean estimated rotavirus vaccination coverage in Spain 
in 2009 was 40%, assuming that all children receive the com-
plete vaccination schedule. This coverage is calculated accord-
ing to the number of distributed doses of each vaccine per year 
(Source: IMS Health) divided by 2 or 3 doses depending on the 
vaccine used, and by the registered number of children under 1 
year of age born for that same period (Source: Spanish National 
Statistics Institute). In the Spanish region of Galicia, that esti-
mated coverage of vaccination was 12% between July 2006 and 
June 2007, 43% between July 2007 and June 2008 and 51% 
between July 2008 and June 2009. In the present study only 
34.9% of recruited children had received at least one vaccine 
dose. This difference between the estimated vaccine coverage 
for our study population (51%) and that found in our sample 
could be explained by the high vaccine efficacy itself that led to 
a dramatic reduction in the need of any kind of medical atten-
tion due to acute gastroenteritis in those children vaccinated. If 
this is considered, the actual vaccine effectiveness may even be 
underestimated in our study.
The vaccine failures detected in our study should be interpreted 
with caution: they where few and only one required hospital admis-
sion. Besides, only fecal immunoassay for rotavirus detection was 
performed in each patient and thus, co-infection cannot be excluded.
There are some limitations to our study: the slightly smaller 
than expected proportion of rotavirus cases, the multicentre 
nature of the study and the high hospitalization rate that might 
oversize hospitalized population.12,13 The previous experience 
of the main team with a similar protocol,14 the specific training 
of the participant subinvestigators distributed throughout the 
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Vaccine failure was defined as a patient having received a full series of either vaccine and presenting AGe by rotavirus.
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